Abstract: Disclosed are compounds comprising analogs of quinic acids or shikimic acids having anti-inflammatory properties. The compounds are suitable for oral administration, stable, and demonstrate significant efficacy in inhibiting NF-kB, inhibiting leukocyte adhesion, and inhibiting other factors and cytokines known to be involved in inflammatory disease.
November 10, 2008
Date of Patent:
February 14, 2012
Charles R. Yates, Duane D. Miller, Kui Zeng, Karin Emmons Thompson
Abstract: Disclosed is a method for amplifying and detecting polynucleotides which can provide sensitive, specific detection of multiple targets from a clinical specimen within a relatively short time.
Abstract: Disclosed is a method for removing endotoxin from proteins. Also disclosed are products made by using the method. The method may be used, for example, to produce endotoxin-free lactoferrin. Bovine milk-derived lactoferrin may be produced in commercial quantities by the method, and endotoxin-free bovine lactoferrin may be used for a variety of therapeutic uses, including improving wound healing.
July 10, 2008
Date of Patent:
April 5, 2011
Glanbia Nutritionals (Ireland), Ltd.
Loren S. Ward, Kevin Thomson, Stanley Wrobel
Abstract: Disclosed is an improved method for preparing the isoflavonoid compound (+/?)-equol, the method comprising reducing an organic diester of the isoflavone daidzein under hydrogen-transfer conditions using palladium hydroxide catalyst.
Abstract: The invention provides cell permeable peptides and peptide agents that inhibit anti-apoptotic processes in cancer cells to promote tumor cell death, as well as a method for providing therapeutic treatment for cancer. The composition may be delivered in conjunction with a conventional chemotherapeutic agent to provide a synergistic effect that significantly increases the effectiveness of the chemotherapeutic agent to destroy cancer cells. The invention also provides kits or systems for cancer therapy, comprising at least one peptide agent for inhibiting the anti-apoptotic effects of NF-kB and at least one chemotherapeutic agent for stimulating the cellular apoptotic pathway.
Abstract: A combination of a chair-like device used by disabled persons, such as a bedside commode, and a seat having a transfer platform that extends laterally outward from a central seating portion of the seat. The extended transfer platform extends beyond the perimeter of the chair frame and at least partially overlaps a supporting surface of a bed or chair that is positioned adjacent to the commode seat. The seat with extended transfer platform thereby provides a continuous transfer surface between the commode or other chair-like device and the adjacent bed or chair.